ProMIS Neurosciences (PMN) Non-Current Assets (2021 - 2026)

ProMIS Neurosciences' (PMN) quarterly Non-Current Assets came in at $1.8 million in Q1 2026, up 9881.57% on a QoQ basis from $18022.0 in Q3 2023.

ProMIS Neurosciences (PMN) Non-Current Assets (2021 - 2026) Analysis & Trends

ProMIS Neurosciences (PMN) has 4 years of Non-Current Assets data on file, last reported at $1.8 million in Q1 2026.

Quarterly Non-Current Assets changed N/A year-over-year to $1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 million (changed N/A YoY) and the FY2022 annual result came in at $21159.0, down 34.46% from the prior year.
Non-Current Assets grew to $1.8 million in Q1 2026, from $18022.0 in the prior quarter.
In the past five years, Non-Current Assets ranged from a high of $1.8 million in Q1 2026 to a low of $18022.0 in Q3 2023.
A 3-year average of $275203.6 and a median of $21159.0 in 2022 frame the typical range for Non-Current Assets.
Annual changes were most pronounced in 2022 — Non-Current Assets tumbled 34.46% — and 2023, when it slipped 19.97%.
Tracing PMN's Non-Current Assets over 3 years: stood at $21159.0 in 2022, then declined by 14.83% to $18022.0 in 2023, then soared by 9881.57% to $1.8 million in 2026.
The last three Non-Current Assets figures came in at $1.8 million (Q1 2026), $18022.0 (Q3 2023), and $18844.0 (Q2 2023), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Assets (Qtr)
1	Vertex Pharmaceuticals	139.66 Bn	131.80 Bn	2.84 Bn	14.88 Bn
2	Regeneron Pharmaceuticals	86.52 Bn	78.53 Bn	3.93 Bn	23.28 Bn
3	Argenx Se	65.33 Bn	60.14 Bn	1.37 Bn	1.96 Bn
4	Moderna	59.76 Bn	54.62 Bn	52.00 Mn	5.15 Bn
5	BeOne Medicines	42.15 Bn	37.05 Bn	1.53 Bn	1.96 Bn
6	Alnylam Pharmaceuticals	31.84 Bn	28.53 Bn	992.69 Mn	938.60 Mn
7	BioNTech SE	28.23 Bn	9.84 Bn	668.28 Mn	6.80 Bn
8	Insmed	27.52 Bn	26.36 Bn	358.27 Mn	468.65 Mn
9	Royalty Pharma	27.29 Bn	26.46 Bn	-	18.06 Bn
10	ProMIS Neurosciences	135.44 Mn	81.98 Mn	-	-

Download Data